Literature DB >> 12172740

Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1.

S A Madhi1, N Ramasamy, K Petersen, A Madhi, K P Klugman.   

Abstract

The aim of this study was to compare the clinical course of severe lower respiratory tract infections associated with human parainfluenza virus types 1-3 (HPIV 1-3) in hospitalised children infected with the human immunodeficiency virus type 1 (HIV-1) versus that in hospitalised children not infected with HIV-1. Children were enrolled prospectively as part of a broader study that evaluated the aetiology of lower respiratory tract infections in HIV-1-infected and -noninfected children from March 1997 through March 1999. HPIV types 1-3 were isolated from nasopharyngeal aspirate samples that were analysed using immunofluorescein monoclonal antibody assays. Thirty percent (24 of 80) of the children from whom HPIV was isolated were infected with HIV-1. Sixty-six percent (47 of 62) and 22% (14 of 62) of the HPIV isolates that were typed were subtypes 3 and 1, respectively. The clinical presentation of severe lower respiratory tract infection was similar in both HIV-1-infected and -noninfected children, except that the former were less likely to have wheezing (4.2% vs. 28.6%, P=0.01). Furthermore, the duration of hospitalisation was longer in HIV-1-infected children than in HIV-1-noninfected children (median 11.5 days [range 1-15 days] vs. median 7.5 days [range 1-22 days]; P=0.02), and mortality was higher (5 of 24 [20.8%] infected children vs. 0 of 56 noninfected children; P=0.001). Importantly, four of five (80%) of the HIV-1-infected children who died had other concurrent illnesses or predisposing factors for severe HPIV-associated disease. HPIV-associated lower respiratory tract infection causes greater morbidity and mortality in HIV-1-infected children than in HIV-1-noninfected children; however, this may be due to other concurrent illnesses in HIV-1-infected children.

Entities:  

Mesh:

Year:  2002        PMID: 12172740     DOI: 10.1007/s10096-002-0754-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Inhibition of human parainfluenza virus type 3 infection by novel small molecules.

Authors:  Hongxia Mao; Chandar S Thakur; Santanu Chattopadhyay; Robert H Silverman; Andrei Gudkov; Amiya K Banerjee
Journal:  Antiviral Res       Date:  2007-10-02       Impact factor: 5.970

2.  N-terminally truncated C protein, CNDelta25, of human parainfluenza virus type 3 is a potent inhibitor of viral replication.

Authors:  Hongxia Mao; Santanu Chattopadhyay; Amiya K Banerjee
Journal:  Virology       Date:  2009-09-10       Impact factor: 3.616

3.  Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase.

Authors:  Ibrahim M El-Deeb; Patrice Guillon; Larissa Dirr; Mark von Itzstein
Journal:  Medchemcomm       Date:  2016-10-05       Impact factor: 3.597

Review 4.  Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries.

Authors:  Miguel Lanaspa; Alicia A Annamalay; Peter LeSouëf; Quique Bassat
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

5.  Case fatality rate and viral aetiologies of acute respiratory tract infections in HIV positive and negative people in Africa: The VARIAFRICA-HIV systematic review and meta-analysis.

Authors:  Sebastien Kenmoe; Jean Joel Bigna; Abdou Fatawou Modiyingi; Marie S Ndangang; Paul Alain Ngoupo; Fredy Brice N Simo; Serges Tchatchouang; Elvis Temfack; Richard Njouom
Journal:  J Clin Virol       Date:  2019-06-28       Impact factor: 3.168

6.  Parainfluenza Virus Infection Among Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Children and Adults Hospitalized for Severe Acute Respiratory Illness in South Africa, 2009-2014.

Authors:  Adam L Cohen; Philip K Sahr; Florette Treurnicht; Sibongile Walaza; Michelle J Groome; Kathleen Kahn; Halima Dawood; Ebrahim Variava; Stefano Tempia; Marthi Pretorius; Jocelyn Moyes; Steven A S Olorunju; Babatyi Malope-Kgokong; Lazarus Kuonza; Nicole Wolter; Anne von Gottberg; Shabir A Madhi; Marietjie Venter; Cheryl Cohen
Journal:  Open Forum Infect Dis       Date:  2015-09-19       Impact factor: 3.835

7.  Hemophilus influenzae and Parainfluenza Virus Pneumonia in a Patient with AIDS.

Authors:  Sandhya Nagarakanti; Eliahu Bishburg
Journal:  Am J Case Rep       Date:  2020-07-11

8.  [Human immunodeficiency virus-infected patients with community-acquired pneumonia: implication of respiratory viruses].

Authors:  Rafael Perelló; Asunción Moreno; Marta Camps; Carlos Cervera; Laura Linares; Tomás Pumarola; María Angeles Marcos
Journal:  Enferm Infecc Microbiol Clin       Date:  2008-02       Impact factor: 1.731

9.  Low mortality rates related to respiratory virus infections after bone marrow transplantation.

Authors:  C M Machado; L S Vilas Boas; A V A Mendes; M F M Santos; I F da Rocha; D Sturaro; F L Dulley; C S Pannuti
Journal:  Bone Marrow Transplant       Date:  2003-04       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.